AIMS/HYPOTHESIS: The aim of this study was to analyse the mechanisms underlying the improvement in glucose tolerance seen in morbidly obese patients undergoing bilio-pancreatic diversion (BPD). SUBJECTS AND METHODS: We evaluated glucose tolerance (by OGTT), insulin sensitivity (euglycaemic-hyperinsulinaemic clamp and the OGTT index OGIS) and beta cell function (OGTT modelling analysis) in 32 morbidly obese (BMI=52+/-7 kg/m(2), mean+/-SD) patients (12 with NGT, 9 with IGT and 11 with type 2 diabetes), before and after BPD, and in 22 lean control subjects. Patients were studied before and from 7 days to 60 months after surgery. RESULTS: BPD improved glucose tolerance in all subjects, who after surgery all had normal glucose tolerance. Insulin sensitivity was restored to normal levels in all subjects (pre-BPD 341+/-79 ml min(-1) m(-2), post-BPD 511+/-57 ml min(-1) m(-2), lean 478+/-49 ml min(-1) m(-2)). The insulin sensitivity change was detectable within 10 days of BPD. At baseline, beta cell sensitivity to glucose was impaired in diabetic subjects (25 [18] pmol min(-1) m(-2) l mmol(-1), median [interquartile range]) compared with lean subjects (82 [98]; p</=0.05). After BPD, beta cell glucose sensitivity showed a tendency towards improvement but remained impaired in diabetic subjects (30 [62]; p<0.01 vs lean). Total insulin output decreased in parallel with the insulin sensitivity increase in all groups. In the whole patient group, mean OGTT glucose levels were inversely related to both insulin sensitivity and beta cell glucose sensitivity (r (2)=0.67, partial r=-0.76 and -0.41, respectively). NEFAs, leptin and adiponectin were related to insulin sensitivity but could not explain the early improvement. CONCLUSIONS/ INTERPRETATION: Following BPD, glucose tolerance was restored mainly as a result of a rapid and large improvement in insulin sensitivity.
AIMS/HYPOTHESIS: The aim of this study was to analyse the mechanisms underlying the improvement in glucose tolerance seen in morbidly obesepatients undergoing bilio-pancreatic diversion (BPD). SUBJECTS AND METHODS: We evaluated glucose tolerance (by OGTT), insulin sensitivity (euglycaemic-hyperinsulinaemic clamp and the OGTT index OGIS) and beta cell function (OGTT modelling analysis) in 32 morbidly obese (BMI=52+/-7 kg/m(2), mean+/-SD) patients (12 with NGT, 9 with IGT and 11 with type 2 diabetes), before and after BPD, and in 22 lean control subjects. Patients were studied before and from 7 days to 60 months after surgery. RESULTS: BPD improved glucose tolerance in all subjects, who after surgery all had normal glucose tolerance. Insulin sensitivity was restored to normal levels in all subjects (pre-BPD 341+/-79 ml min(-1) m(-2), post-BPD 511+/-57 ml min(-1) m(-2), lean 478+/-49 ml min(-1) m(-2)). The insulin sensitivity change was detectable within 10 days of BPD. At baseline, beta cell sensitivity to glucose was impaired in diabetic subjects (25 [18] pmol min(-1) m(-2) l mmol(-1), median [interquartile range]) compared with lean subjects (82 [98]; p</=0.05). After BPD, beta cell glucose sensitivity showed a tendency towards improvement but remained impaired in diabetic subjects (30 [62]; p<0.01 vs lean). Total insulin output decreased in parallel with the insulin sensitivity increase in all groups. In the whole patient group, mean OGTT glucose levels were inversely related to both insulin sensitivity and beta cell glucose sensitivity (r (2)=0.67, partial r=-0.76 and -0.41, respectively). NEFAs, leptin and adiponectin were related to insulin sensitivity but could not explain the early improvement. CONCLUSIONS/ INTERPRETATION: Following BPD, glucose tolerance was restored mainly as a result of a rapid and large improvement in insulin sensitivity.
Authors: S B Heymsfield; S Lichtman; R N Baumgartner; J Wang; Y Kamen; A Aliprantis; R N Pierson Journal: Am J Clin Nutr Date: 1990-07 Impact factor: 7.045
Authors: Francesco Rubino; Michel Gagner; Paolo Gentileschi; Subhash Kini; Shoji Fukuyama; John Feng; Ed Diamond Journal: Ann Surg Date: 2004-08 Impact factor: 12.969
Authors: P A Tataranni; G Mingrone; A V Greco; P Caradonna; E Capristo; C A Raguso; A De Gaetano; R M Tacchino; M Castagneto Journal: Am J Clin Nutr Date: 1994-09 Impact factor: 7.045
Authors: Jill P Crandall; William C Knowler; Steven E Kahn; David Marrero; Jose C Florez; George A Bray; Steven M Haffner; Mary Hoskin; David M Nathan Journal: Nat Clin Pract Endocrinol Metab Date: 2008-05-20
Authors: Carmine Finelli; Maria Carmela Padula; Giuseppe Martelli; Giovanni Tarantino Journal: World J Gastroenterol Date: 2014-11-28 Impact factor: 5.742
Authors: Ana Carolina Junqueira Vasques; José Carlos Pareja; José Roberto Mattos Souza; Ademar Yamanaka; Maria da Saúde de Oliveira; Fernanda Satake Novaes; Élinton Adami Chaim; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Bruno Geloneze Journal: Obes Surg Date: 2015-03 Impact factor: 4.129
Authors: Carsten Dirksen; Kirstine N Bojsen-Møller; Nils B Jørgensen; Siv H Jacobsen; Viggo B Kristiansen; Lars S Naver; Dorte L Hansen; Dorte Worm; Jens J Holst; Sten Madsbad Journal: Diabetologia Date: 2013-09-19 Impact factor: 10.122